A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Nelmastobart (Primary) ; Bevacizumab; Tipiracil/trifluridine
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors STCube Pharmaceuticals
Most Recent Events
- 15 Jun 2025 Planned number of patients changed from 70 to 52.
- 15 Jun 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Mar 2025 New trial record